Community Oncology Alliance
2021 Data on HCC & mCRC: Atezo+Bev vs. Sorafenib in Unresectable HCC; Pembro vs. Chemo for MMR/MSI-H CRC, Encorafenib+Cetuximab in BRAF V600E Mutations, Trastuzumab+Tucatinib for HER2-Amplified CRC
By
2021 Community Oncology Conference
FEATURING
Johanna Bendell
By
2021 Community Oncology Conference
FEATURING
Johanna Bendell
Login to view comments.
Click here to Login